Amphastar Pharmaceuticals Inc (AMPH)
38.63
-1.42
(-3.55%)
USD |
NASDAQ |
Apr 18, 16:00
38.64
+0.02
(+0.04%)
After-Hours: 20:00
Amphastar Pharmaceuticals Revenue (Quarterly): 178.10M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 178.10M |
| September 30, 2023 | 180.56M |
| June 30, 2023 | 145.71M |
| March 31, 2023 | 140.02M |
| December 31, 2022 | 135.02M |
| September 30, 2022 | 120.13M |
| June 30, 2022 | 123.47M |
| March 31, 2022 | 120.37M |
| December 31, 2021 | 120.89M |
| September 30, 2021 | 112.20M |
| June 30, 2021 | 101.66M |
| March 31, 2021 | 103.02M |
| December 31, 2020 | 95.92M |
| September 30, 2020 | 83.43M |
| June 30, 2020 | 85.81M |
| March 31, 2020 | 84.69M |
| December 31, 2019 | 83.38M |
| September 30, 2019 | 80.14M |
| June 30, 2019 | 79.05M |
| March 31, 2019 | 79.79M |
| December 31, 2018 | 89.69M |
| September 30, 2018 | 75.54M |
| Date | Value |
|---|---|
| June 30, 2018 | 71.04M |
| March 31, 2018 | 58.39M |
| December 31, 2017 | 60.40M |
| September 30, 2017 | 57.92M |
| June 30, 2017 | 65.19M |
| March 31, 2017 | 56.67M |
| December 31, 2016 | 63.54M |
| September 30, 2016 | 64.22M |
| June 30, 2016 | 68.03M |
| March 31, 2016 | 59.37M |
| December 31, 2015 | 76.91M |
| September 30, 2015 | 63.87M |
| June 30, 2015 | 53.85M |
| March 31, 2015 | 56.89M |
| December 31, 2014 | 55.88M |
| September 30, 2014 | 59.71M |
| June 30, 2014 | 49.00M |
| March 31, 2014 | 45.87M |
| December 31, 2013 | 54.88M |
| September 30, 2013 | 59.32M |
| June 30, 2013 | 62.52M |
| March 31, 2013 | 52.96M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
79.05M
Minimum
Jun 2019
180.56M
Maximum
Sep 2023
114.40M
Average
112.20M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 9.353B |
| Dentsply Sirona Inc | 1.012B |
| Pacira BioSciences Inc | 181.24M |
| Organon & Co | 1.598B |
| NovaBay Pharmaceuticals Inc | 3.727M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 36.17M |
| Total Expenses (Quarterly) | 124.12M |
| EPS Diluted (Quarterly) | 0.68 |
| Enterprise Value | 2.191B |
| Gross Profit Margin (Quarterly) | 53.98% |
| Profit Margin (Quarterly) | 20.31% |
| Earnings Yield | 6.68% |
| Operating Earnings Yield | 9.62% |
| Normalized Earnings Yield | 6.679 |